TNFRSF17 and plasma cell myeloma: Therefore, further investigations will focus on anti-BCMA based therapy alone or in combination with other anti-myeloma drugs as an evolving concept in patients with relapsed or refractory MM or even in newly diagnosed MM to consistently improve the outcome towards a cure.